PRESS-RELEASE ·Filed Mar 24, 2026

PVLA

Palvella Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight • Neutral

Traders should monitor the March 31 earnings call for potential updates on clinical progress, cash runway, or funding needs, which could impact valuation given the company's pre-revenue status.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
PVLA ▼ -2.69% at T+60d
NEUTRAL call ✗ call lost -2.69% · α vs SPY -17.02% · entry $116.23 → $113.10
Entry anchored
Mar 23, 03:59 PM ET
via exchange tick
T+1d
+3.58%
call +3.58% · α +3.01%
$120.39
settled 6mo ago
T+5d
+7.24%
call +7.24% · α +7.67%
$124.65
settled 6mo ago
T+20d
+12.40%
call +12.40% · α +3.50%
$130.64
settled 5mo ago
T+60d
-2.69%
call -2.69% · α -17.02%
$113.10
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Palvella Therapeutics announced it will report its full year 2025 financial results on March 31, 2026, followed by a conference call to discuss the results and provide a corporate update. The press release contains no actual financial data, only logistical details about the upcoming earnings announcement.

Key Facts

  • Palvella Therapeutics will report full year 2025 financial results on March 31, 2026, before market open.
  • Management will host a conference call at 8:30 a.m. ET on March 31, 2026, to discuss results and provide a corporate update.
  • No financial results, guidance, or operational updates were disclosed in this release.
  • Company remains in clinical-stage development with no FDA-approved therapies yet.

Financial Impact

No financial data disclosed in this release

Risk Factors

  • No revenue-generating products; dependent on clinical trial outcomes and future financing.
  • Failure to meet clinical or regulatory milestones could negatively impact stock price.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3261100
24 reports for PVLA
Performance horizon
67% Hit rate 4 of 6 directional calls best @ T+60▲ +35.07%May 15, 2026
Filters
Rows
Reports for PVLA — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
144
NEUTRAL ★ 2/10
$155.47 $132.47▼ −14.79%▼ −13.61%$132.47 (−14.79%)
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 6/10
$152.22 $157.00▲ +3.14%▲ +4.05%$132.47 (−12.97%)
Aug 4, 2026
8w ago
8-K
NEUTRAL ★ 5/10
$151.99 $150.55▼ −0.95%▲ +0.29%$132.47 (−12.84%)
Jul 30, 2026
9w ago
Press Release
NEUTRAL ★ 2/10
$150.19 $150.33▲ +0.09%▼ −3.87%$132.47 (−11.80%)
Jul 28, 2026
9w ago
Press Release
NEUTRAL ★ 2/10
$142.84 $148.24▲ +3.78%▲ +0.40%$132.47 (−7.26%)
Jun 30, 2026
13w ago
8-K
NEUTRAL ★ 2/10
$152.82 $141.77▼ −7.23%▼ −6.20%$132.47 (−13.32%)
Jun 22, 2026
14w ago
Press Release
BULLISH ★ 7/10
$118.84 $157.24▲ +32.31%▲ +32.46%$132.47 (+11.47%)
Jun 16, 2026
15w ago
8-K
NEUTRAL ★ 2/10
$110.12 $149.68▲ +35.92%▲ +35.72%$132.47 (+20.30%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$106.38 $151.04▲ +41.98%▲ +40.09%$132.47 (+24.53%)
May 15, 2026
20w ago
8-K
NEUTRAL ★ 4/10
$114.24 $116.51▲ +1.99%▼ −0.13%$132.47 (+15.96%)
Showing 10 of 24

US Market Status

Market Closed — Opens Mon (63h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 24, 2026